The Lasting Immunological Footprint of VITT – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Adam Kanack et al, adding:
”Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia
In VITT patients, anti-PF4 antibodies persist as monoclonal/oligoclonal clones without epitope spreading, with one case showing platelet-activating antibodies four years post-event.”
Title: Platelet factor 4 antibody persistence and long-term pathogenicity in vaccine-induced immune thrombotic thrombocytopenia
Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi Smock, David Green, Jonathan Coker, Mindy Kohlhagen, David Murray, Anand Padmanabhan

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 00:23Saji Kumar: The Role of Agentic AI in Blood Bank Inventory Coordination
-
Nov 14, 2026, 00:04Carlos A. Metidieri Menegozzo: The First Priority in Trauma Transfusion May Be Time to First Blood Product
-
Nov 13, 2026, 23:43Alamgir Hosen Ronit: Corrected Platelet Count in EDTA Induced Platelet Aggregation
-
Nov 13, 2026, 23:32Evi Loos: Can PRP Improve Pain in Thumb Base Osteoarthritis?
-
Nov 13, 2026, 23:10Cesar de Almeida Neto: Digital Connectivity Can Transform Plateletpheresis Practice
-
Nov 13, 2026, 23:10Chien-Wen Liew: Where PRP Actually Sits in the Evidence
-
Nov 13, 2026, 23:08Erika Koppers: Continuing the Collaborative Journey Towards Equitable Haemophilia Care in South Africa
-
Nov 13, 2026, 23:06Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
-
Nov 13, 2026, 22:57Rolf Bekendam: Moderating a Conversation With Experts on Rare Bleeding Disorders